Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.

about

Functional evaluation of therapeutic response of HCC827 lung cancer to bevacizumab and erlotinib targeted therapy using dynamic contrast-enhanced and diffusion-weighted MRI.

Item

http://www.wikidata.org/entity/Q45933675

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Functional evaluation of thera ...... ed and diffusion-weighted MRI.

@en

Functional evaluation of thera ...... ed and diffusion-weighted MRI.

@nl

type

Item

label

Functional evaluation of thera ...... ed and diffusion-weighted MRI.

@en

Functional evaluation of thera ...... ed and diffusion-weighted MRI.

@nl

prefLabel

Functional evaluation of thera ...... ed and diffusion-weighted MRI.

@en

Functional evaluation of thera ...... ed and diffusion-weighted MRI.

@nl

P1476

Functional evaluation of thera ...... ced and diffusion-weighted MRI

@en

P2093

Jyh-Horng Chen

http://www.w3.org/2001/XMLSchema#string

Kuan-Hung Cho

http://www.w3.org/2001/XMLSchema#string

Mark Yen-Ping Kuo

http://www.w3.org/2001/XMLSchema#string

Yi-Chien Lu

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling.

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors

Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer

BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations

P304

e0187824

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0187824

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Yeun-Chung Chang

Ang Yuan

Yi-Fang Chen

P577

2017-11-09T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29121075

http://www.w3.org/2001/XMLSchema#string

P921

bevacizumab

P932

5679602

http://www.w3.org/2001/XMLSchema#string